Page 107 - EJMO-9-3

Eurasian Journal of
Medicine and Oncology Novel senescence-based melanoma risk model

28. Newman AM, Liu CL, Green MR, et al. Robust enumeration Commun. 2020;11(1):1839.
of cell subsets from tissue expression profiles. Nat Methods. doi: 10.1038/s41467-020-15538-9
2015;12(5):453-457.
35. Bogunovic D, O’Neill DW, Belitskaya-Levy I, et al. Immune
doi: 10.1038/nmeth.3337 profile and mitotic index of metastatic melanoma lesions
29. Jacquelot N, Duong CPM, Belz GT, Zitvogel L. Targeting enhance clinical staging in predicting patient survival. Proc
chemokine and chemokine receptors in melanoma and Natl Acad Sci U S A. 2009;106(48):20429-20434.
other cancers. Front Immunol. 2018;9:2480. doi: 10.1073/pnas.0905139106
doi: 10.3389/fimmu.2018.02480 36. Homann L, Rentschler M, Brenner E, Bohm K, Rocken M,
30. Cesati M, Scatozza F, D’Arcangelo D, et al. Investigating Wieder T. IFN-γ gamma and TNF induce senescence and
serum and tissue expression identified a cytokine/ a distinct senescence-associated secretory phenotype in
chemokine signature as a highly effective melanoma marker. melanoma. Cells. 2022;11(9):1514.
Cancers (Basel). 2020;12(12):3680. doi: 10.3390/cells11091514
doi: 10.3390/cancers12123680 37. Safi M, Jin C, Aldanakh A, et al. Immune checkpoint inhibitor
31. Ziogas DC, Theocharopoulos C, Koutouratsas T, Haanen J, (ICI) genes and aging in malignant melanoma patients:
Gogas H. Mechanisms of resistance to immune checkpoint A clinicogenomic TCGA study. BMC Cancer. 2022;22(1):978.
inhibitors in melanoma: What we have to overcome? Cancer doi: 10.1186/s12885-022-09860-2
Treat Rev. 2023;113:102499.
38. Fukuda K. Networks of CD8 T cell response activation in
+
doi: 10.1016/j.ctrv.2022.102499 melanoma and vitiligo. Front Immunol. 2022;13:866703.
32. Nirmal AJ, Maliga Z, Vallius T, et al. The spatial landscape doi: 10.3389/fimmu.2022.866703
of progression and immune editing in primary melanoma at
single-cell resolution. Cancer Discov. 2022;12(6):1518-1541. 39. Zeng N, Guo C, Wang Y, et al. Characterization of aging-
related genes to predict prognosis and evaluate the tumor
doi: 10.1158/2159-8290.CD-21-1357 immune microenvironment in malignant melanoma.
33. Gaydosik AM, Tabib T, Geskin LJ, et al. Single-cell lymphocyte J Oncol. 2022;2022:1271378.
heterogeneity in advanced cutaneous t-cell lymphoma skin doi: 10.1155/2022/1271378
tumors. Clin Cancer Res. 2019;25(14):4443-4454.
40. Liang X, Lin X, Lin Z, Lin W, Peng Z, Wei S. Genes associated
doi: 10.1158/1078-0432.CCR-19-0148 with cellular senescence favor melanoma prognosis by
stimulating immune responses in tumor microenvironment.
34. Mitra A, Andrews MC, Roh W, et al. Spatially resolved
analyses link genomic and immune diversity and reveal Comput Biol Med. 2023;158:106850.
unfavorable neutrophil activation in melanoma. Nat doi: 10.1016/j.compbiomed.2023.106850

Volume 9 Issue 3 (2025) 99 doi: 10.36922/ejmo.8574